Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 14, Issue -, Pages 166-168Publisher
ELSEVIER SCI LTD
DOI: 10.1111/j.1469-0691.2007.01859.x
Keywords
Escherichia coli; extended-spectrum beta-lactamase; Monte-Carlo simulation; pharmacodynamics; pharmacokinetics; review
Categories
Ask authors/readers for more resources
An understanding of antibacterial pharmacokinetics and pharmacodynamics is central to setting clinical breakpoints. It is important to understand any impact that a resistance mechanism may have on these basic drug properties. With extended-spectrum P-lactamase (ESBL)-producing strains of Enterobacteriacae, it is known that MIC, and hence T>MIC, for beta-lactams predicts outcome. Therefore, pharmacodynamic modelling can be used to set breakpoints for ESBL-producing bacteria with beta-lactams.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available